hVIVO signs £2.5m contract for Omicron characterisation study
hVIVO plc (LON:HVO), a fast growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, has announced that it has signed a £2.5m